Impact of Direct Oral Anticoagulants in Patients With Hip Fractures

J Orthop Trauma. 2019 Jan;33(1):e8-e13. doi: 10.1097/BOT.0000000000001329.

Abstract

Objective: To assess the impact of direct oral anticoagulant (DOAC) intake compared with Coumadin (COU) in patients suffering hip fractures (HFs).

Design: Retrospective cohort analysis.

Setting: Level 1 Trauma Center.

Intervention: Timing of surgical hip fixation.

Patients: Three-hundred twenty patients 65 years of age or older with isolated HF were enrolled into the study: 207 (64.7%) without any antithrombotic therapy (no-ATT), 59 (18.4%) on COU, and 54 (16.9%) on DOACs.

Main outcome measurements: Time to surgery, blood loss, mortality, hospital length of stay, red blood cell transfusion, use of reversal agents, and Charlson Comorbidity Index.

Results: Patients on COU and DOACs had a higher Charlson Comorbidity Index compared with the no-ATT group (P < 0.0001). Despite the fact that significantly more patients received reversal agents in the COU group compared with DOAC medication (P < 0.0001), percentage of transfused patients were similar (54.2% vs. 53.7%). Time to surgery was significantly shorter in the no-ATT group when compared with DOAC patients (12-29.5 hours, respectively). No difference in postoperative hemorrhage, intensive care unit length of stay, and mortality was observed between groups.

Conclusions: DOAC medication in HF patients caused long elapse time until surgical repair. We found no evidence of higher bleeding rates in HF patients on DOACs compared with COUs. Earlier HF fixation might be indicated in DOAC patients.

Level of evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

MeSH terms

  • Administration, Oral
  • Aged
  • Anticoagulants / therapeutic use*
  • Female
  • Fracture Fixation*
  • Hip Fractures / complications
  • Hip Fractures / mortality
  • Hip Fractures / surgery*
  • Humans
  • Length of Stay
  • Male
  • Postoperative Hemorrhage / epidemiology*
  • Retrospective Studies
  • Survival Rate
  • Time-to-Treatment
  • Treatment Outcome
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Warfarin